Tozorakimab Cuts COPD Exacerbations Up to 34% in Phase 3 Trials

Tozorakimab, an investigational monoclonal antibody targeting IL-33, reduced moderate to severe COPD exacerbations by up to 34% in two phase 3 trials across smoking status and eosinophil levels, positioning it as a potential new add-on therapy for a broader COPD patient population.

This Wire brief sits within Fusion42's coverage of Medtech and Drug Discovery.